Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis

作者：Fan, Xiaoqiang; Zhang, Xiu; Shen, Jie^*; Zhao, Haibin; Yu, Xuetao; Chen, Yong'an; Zhuang, Zhuonan; Deng, Xiaolong; Feng, Hua; Wang, Yunfei; Peng, Long

来源：PLos One, 2016, 11(2): e0149028.

DOI：10.1371/journal.pone.0149028

• NF-KAPPA-B
• OVARIAN-CANCER
• ADJUVANT CHEMOTHERAPY
• PLUS GEMCITABINE
• SURVIVAL
• TRIAL
• ADENOCARCINOMA
• RESECTION
• IMPACT
• CARCINOGENESIS

Pancreatic cancer is an aggressive disease with dismal prognosis. It is of paramount importance to understand the underlying etiological mechanisms and identify novel, consistent, and easy-to-apply prognostic factors for precision therapy. TUSC3 (tumor suppressor candidate 3) was identified as a potential tumor suppressor gene and previous study showed TUSC3 is decreased in pancreatic cancer at mRNA level, but its putative tumor suppressor function remains to be verified. In this study, TUSC3 expression was found to be suppressed both at mRNA and protein levels in cell line models as well as in clinical samples; decreased TUSC3 expression was associated with higher pathological TNM staging and poorer outcome. In three pairs of cell lines with different NF-kappa B activity, TUSC3 expression was found to be reversely correlated with NF-kappa B activity. TUSC3-silenced pancreatic cancer cell line exhibited enhanced potential of proliferation, migration and invasion. In an orthotopic implanted mice model, TUSC3 silenced cells exhibited more aggressive phenotype with more liver metastasis. In conclusion, the current study shows that decreased immunological TUSC3 staining is a factor prognostic of poor survival in pancreatic cancer patients and decreased TUSC3 promotes pancreatic cancer cell proliferation, invasion and metastasis. The reverse correlation between NF-kappa B activity and TUSC3 expression may suggest a novel regulation pattern for this molecule.

• 出版日期2016-2-12
• 单位山东大学